Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01491711|
Recruitment Status : Unknown
Verified January 2014 by Maastricht University Medical Center.
Recruitment status was: Recruiting
First Posted : December 14, 2011
Last Update Posted : January 31, 2014
Skin cancer is the most common cancer in Caucasians, and a basal cell carcinoma (BCC) being the most common skin cancer with around 44,000 new tumours per year, and its incidence is still rising. In the past it has been a disease of the elderly patient but as a consequence of recreational sun exposure and tanning beds, more young patients develop a skin cancer as well. There are different subtypes of BCC and most subtypes are treated by surgical excision. Nowadays, non-invasive techniques as photodynamic therapy (PDT) are common practice to treat superficial BCC (sBCC). Because of these techniques treatment by surgical excision can be avoided with the possibility of complications and scar formation. Both 5-aminolevulino acid (5-ALA) and the more lipophilic methyl aminolevulinate (MAL) can be used as a precursor of the photosensitiser. These agents generate an excess of protoporphyrin IX in metabolic active cells, which are illuminated by a specific light source leading to release of reactive oxygen radicals in tissue. The result is apoptosis and necrosis of tumour cells. At the moment, two treatment protocols are used in the Netherlands: the fractionated 5-ALA 20% (Fagron) protocol according to de Haas and the MAL (Metvix, Galderma) protocol. Because MAL was first marketed and registered as a treatment option for premalignant and superficial malignancies most hospitals in the Netherlands use this topical agent. However, there is no evidence which of the 2 agents is more (cost-)effective and/ or preferred by patients.
Objective: to determine which treatment is the most effective treatment in terms of prevention of treatment failure, cost saving and patients preference when comparing fractionated 5-ALA 20% PDT versus MAL PDT in 2 treatment sessions.
|Condition or disease||Intervention/treatment||Phase|
|Superficial Basal Cell Carcinoma||Drug: Methylaminolevulinate PDT in 2 sessions Drug: Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT||Phase 4|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||162 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Treatment of Superficial Basal Cell Carcinoma by Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Topical Photodynamic Therapy With Methylaminolevulinate|
|Study Start Date :||August 2013|
|Estimated Primary Completion Date :||April 2015|
|Estimated Study Completion Date :||April 2015|
Active Comparator: Fractionated 5-ALA HCl 20% gel PDT
Twice on day 1
Drug: Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
The 5-ALA HCl 20% gel is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm). During illumination a fan is used to cool the treatment site. The treatment site is covered again with Tegaderm for 2 hours after first treatment, whereupon a second illumination with the same light takes place. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs. Patients are advised to avoid direct sunlight two days after treatment.
Active Comparator: Methylaminolevulinate PDT in 2 sessions
On day 1 and 8
Drug: Methylaminolevulinate PDT in 2 sessions
The methylaminolevulinate creme is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm, 570-670 nm, 75 J/cm2). The light intensity at the lesion surface should not exceed 200 mW/cm2. During illumination a fan is used to cool the treatment site. After the first treatment the skin area is covered to prevent exposure to daylight during 48 hours. After one week (on day 8), the same procedure is repeated. After the treatment the skin area is covered to prevent exposure to daylight during 48 hours. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs.
- Treatment failure [ Time Frame: 12 months posttreatment ]Histological proven treatment failure one year after treatment of sBCC with fractionated 5-ALA 20% PDT versus MAL PDT in 2 sessions. If there is any clinical suspicion of residual tumour at control visits 3 and 12 months posttreatment, a 3 mm punch biopsy will be taken to confirm the diagnosis by histopathology.
- Patient preferences [ Time Frame: 1 week posttreatment ]
Patient preferences of treatment with fractionated 5-ALA 20% PDT versus MAL PDT in 2 sessions.
A patient questionnaire will be given twice: on last day of treatment and 1 week posttreatment
- Health care costs [ Time Frame: 12 months posttreatment ]Health care costs of treatment with fractionated 5-ALA 20% PDT versus MAL PDT in 2 sessions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01491711
|Contact: Nicole WJ Kelleners-Smeets, MD, PhDfirstname.lastname@example.org|
|Contact: Janneke JPHM Kessels, MDemail@example.com|
|Maastricht University Medical Center||Recruiting|
|Maastricht, Limburg, Netherlands, 6202 AZ|
|Contact: N WJ Kelleners-Smeets, MD, PhD 0031433877295 firstname.lastname@example.org|
|Contact: J JPHM Kessels, MD 0031433877295 email@example.com|
|VieCuri Medical Centre||Recruiting|
|Venlo, Limburg, Netherlands, 5912 BL|
|Contact: J PA van Pelt, MD, PhD|
|Contact: M JM van Rooij, MD, PhD|
|Erasmus Medical Centre||Recruiting|
|Rotterdam, Zuid-Holland, Netherlands, 3015 CE|
|Contact: E RM de Haas, MD, PhD 0031107034849 firstname.lastname@example.org|
|Contact: H Kreukels, MD 0031107040110 email@example.com|